Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Pulmonary Arterial Hypertension (TRANSFORM-UK)
NCT02676947Phase 2Completed
- Start
- Jan 2016
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in pulmonary arterial hypertension (PAH). Started Jan 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02676947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676947.